Dilip Shanghvi net worth stood at about $24.8 billion in April 2026, according to Forbes. That’s roughly ₹2 lakh crore. A year earlier, in May 2025, Forbes put it at $28.9 billion and ranked him India’s fifth richest person.
Almost all of it ties back to one company. Sun Pharmaceutical Industries is India’s most valuable listed drugmaker, with a market value above $40 billion. The Shanghvi family’s stake in Sun Pharma is the core of the fortune.
So when the share price moves, so does the Dilip Shanghvi net worth figure. That’s why the 2025 and 2026 estimates differ by about $4 billion.
The start was tiny. In 1983, Dilip Shanghvi borrowed a small sum from his father and set up a single plant in Gujarat to make psychiatric drugs.
Who Is Dilip Shanghvi?
He’s the founder of Sun Pharma and one of India’s best-known first-generation entrepreneurs. His Dilip Shanghvi biography begins in Amreli, Gujarat, where he was born on 1 October 1955.
The family later moved to Kolkata. His father ran a small wholesale business there, trading in generic medicines, and young Dilip helped out. That’s where he learned how the medicine trade really works.
As for Dilip Shanghvi education qualification, he has a Bachelor of Commerce (B.Com) from the University of Calcutta. He didn’t study science or engineering. His training in pharma came from the shop counter.
Going by his date of birth, Dilip Shanghvi age is 71 in 2026.
Dilip Shanghvi Sun Pharma: From One Plant to a Global Drugmaker
Sun Pharma launched in 1983 with a narrow focus on psychiatric medicines. Its only plant was in Vapi, Gujarat. Bigger firms weren’t paying much attention to that niche, which gave a small company room to grow.
Growth came in steps, and then in leaps. The biggest leap came in 2014, when Sun Pharma bought Ranbaxy Laboratories for about $4 billion. That deal made it India’s largest drugmaker.
More buys followed. Ocular Technologies joined in 2016 and Concert Pharmaceuticals in 2023. In 2025 came Checkpoint Therapeutics, a US company working on skin cancer drugs, for $355 million.
Today, about two-thirds of Sun Pharma’s revenue comes from outside India. The company is also moving into specialty medicines for skin conditions, cancer and obesity, where margins tend to be higher.
The Organon Deal: Dilip Shanghvi’s Biggest Business Bet
In April 2026, Sun Pharma agreed to buy Organon & Co, a US company focused on women’s health. The price is about $11.75 billion including debt, paid fully in cash at $14 a share.
It’s the largest foreign acquisition ever agreed by an Indian drugmaker. For the Dilip Shanghvi business story, it’s also the boldest move since Ranbaxy.
Sun Pharma’s own numbers give it room. In the year to March 2026 (FY26), revenue was ₹58,220 crore and net profit was ₹11,479 crore.
Dilip Shanghvi Children and the Family at Sun Pharma
His wife is Vibha Shanghvi. Both Dilip Shanghvi children, Aalok and Vidhi, work at the Dilip Shanghvi company.
Aalok Dilip Shanghvi has taken on a bigger role. In 2025 he was named chief operating officer. That’s an important step for a founder-led firm thinking about the next generation.
Family ties also run through the board. Sudhir Valia, Dilip’s brother-in-law, has been a long-time director, and the Sudhir Valia Sun Pharma connection goes back many years.
Dilip Shanghvi Awards and Public Roles
The government awarded him the Padma Shri in 2016. Back in 2005, he was named EY Entrepreneur of the Year for India.
His roles go beyond Sun Pharma. In 2018 he was appointed to the central board of the Reserve Bank of India (RBI). He also chairs the board of governors of IIT Bombay.
Dilip Shanghvi Forbes Ranking: Why It Moves
Forbes counts his wealth mainly through the family’s Sun Pharma shares. When the stock rises, the estimate rises. When it falls, the number drops.
That’s why the Dilip Shanghvi Forbes figure fell from $28.9 billion in May 2025 to $24.8 billion in April 2026. The business didn’t shrink by that much. The market price did the work.
What Investors Can Learn From This
Starting narrow can work. Sun Pharma began with one plant and one type of medicine. Deep knowledge of a small market gave it a base to build on.
Acquisitions help only when they fit. Ranbaxy added scale in generics. Organon adds a women’s health business abroad. Each deal pushed an existing plan forward.
Concentration cuts both ways. A fortune held mostly in one stock can grow fast, and it can also drop by billions in a year, as the Forbes numbers show.
Long timelines matter. Sun Pharma took more than four decades to reach its current size. Patience was a big part of the result.
Frequently Asked Questions
1. What is Dilip Shanghvi’s net worth in 2026?
Forbes estimated it at about $24.8 billion in April 2026, which is roughly ₹2 lakh crore.
2. Who is Dilip Shanghvi?
He’s the founder of Sun Pharmaceutical Industries, India’s most valuable listed drugmaker.
3. What is Dilip Shanghvi’s date of birth?
He was born on 1 October 1955 in Amreli, Gujarat.
4. What is Dilip Shanghvi’s education qualification?
He holds a B.Com degree from the University of Calcutta.
5. Which company did Sun Pharma agree to buy in 2026?
It agreed to buy Organon & Co, a US women’s health company, for about $11.75 billion including debt.
6. Who is Aalok Dilip Shanghvi?
He’s Dilip Shanghvi’s son. He works at Sun Pharma and became its chief operating officer in 2025.
Disclaimer: This article is for general information only. Net worth figures are Forbes estimates and change with share prices. This isn’t investment, tax or legal advice.







